EPI

Envision Peripherals Inc. (EPI) Announces Tom Guagliardi as New Director of Sales

Retrieved on: 
Tuesday, February 21, 2023
Philips, Education, Growth, B2B, DMR, Government, EPI, Sales

MILPITAS, Calif., Feb. 21, 2023 /PRNewswire-PRWeb/ -- Envision Peripherals Inc. (EPI), the sole distributor of Philips-branded monitors and peripheral products for business, education, government, and consumers use in US, is pleased to announce that Tom Guagliardi has joined the team as the new B2B Director of Sales for US and Director of Sales for Canada. In this role, Guagliardi will be responsible for leading the company's sales efforts and driving growth in the highly competitive commercial market.

Key Points: 
  • In this role, Guagliardi will be responsible for leading the company's sales efforts and driving growth in the highly competitive commercial market.
  • Guagliardi brings more that 20 years of experience in the IT industry including manufacturing, distribution in sales, and leadership, in both US and Canada.
  • Guagliardi is excited to join EPI and looks forward to working with the team to achieve its sales goals.
  • "I am thrilled to be joining EPI and to have the opportunity to help drive the company's sales growth," he said.

First Wave BioPharma Announces Phase 2 Adrulipase Combination Trial Data to be Presented at the 2023 Digestive Disease Week (DDW) Conference

Retrieved on: 
Tuesday, February 21, 2023
CF, Patient, DDW, Cystic fibrosis, Safety, Steatorrhea, Human, CP, Incidence, Body mass index, Clinical trial, EPI, Translation, Exocrine pancreatic insufficiency, Absorption, Open-label trial, Defecation, PERT, Survival, Combination, PPE, Candace Pert, BOCA, First wave, Conference, SPAN, Case Western Reserve University School of Medicine, Pharmaceutical industry, CFA

The conference is taking place May 6-9, 2023, in Chicago.

Key Points: 
  • The conference is taking place May 6-9, 2023, in Chicago.
  • “The research presented at DDW 2023 is intended to highlight the potential benefits that adrulipase may offer in the treatment of EPI above and beyond PERT, the current standard of care,” stated James Sapirstein, President and CEO of First Wave BioPharma.
  • Adding a synthetic lipase like adrulipase to PERT has demonstrated the potential to improve fat absorption and overall nutrition of CF patients.
  • The digestive standard of care for both CF and chronic pancreatitis (CP) patients with EPI are commercially available PERTs.

First Wave BioPharma Chairman and CEO Issues Letter to Stockholders

Retrieved on: 
Monday, February 13, 2023
Capsule, Stomach, Patent, Biotechnology, Enzyme replacement therapy, Hope, CF, Patient, Biologics license application, Cystic fibrosis, Safety, CNA, CP, Clinical trial, EPI, CFA, Research, Health, Letter, Food, Exocrine pancreatic insufficiency, Malabsorption, PERT, IP, BOCA, First wave, Quality of life, BLA, Gastrointestinal disease, Pharmaceutical industry

BOCA RATON, Fla., Feb. 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman, President and CEO of First Wave BioPharma, has issued a Letter to Stockholders providing an update on the Company’s clinical programs and recent events.

Key Points: 
  • BOCA RATON, Fla., Feb. 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman, President and CEO of First Wave BioPharma, has issued a Letter to Stockholders providing an update on the Company’s clinical programs and recent events.
  • First Wave BioPharma was not immune to this unfortunate trend, but we weathered the storm.
  • We look forward to capitalizing on several growth drivers in 2023 and reaching our next clinical milestone.
  • Phase 2 Adrulipase Trial Initiated, Topline Data Expected in Mid-2023
    Key to our value proposition is the advancement of our adrulipase program.

Electromedical Products International, Inc., Awards First Annual Innovative Young Investigator in Brain Stimulation Award

Retrieved on: 
Wednesday, February 15, 2023
Alternative Medicine, Mental Health, Medical Devices, Health, Neurology, Health Technology, Colonial Life Arena, International Brain Research Organization, Q&A, DSM-IV codes, Travel, EPI, Research, Clinical research, Defence Bioengineering and Electromedical Laboratory, Office Products International, Conference, Psychiatry, Medical device

Electromedical Products International, Inc. (EPI), manufacturer of Alpha-Stim® technology , announced today that it has awarded its first annual Innovative Young Investigator in Brain Stimulation Award to Tobias Schwippel, M.D.

Key Points: 
  • Electromedical Products International, Inc. (EPI), manufacturer of Alpha-Stim® technology , announced today that it has awarded its first annual Innovative Young Investigator in Brain Stimulation Award to Tobias Schwippel, M.D.
  • EPI established this award to recognize and nurture excellence in the field of non-invasive brain stimulation.
  • Recipients are early-career researchers making notable, innovative contributions in the field who demonstrate the potential to be leaders in clinical research and practice.
  • Dr. Tobias Schwippel, Director of Clinical Research at the Carolina Center for Neurostimulation , focuses on non-invasive brain stimulation research in psychiatry.

China Vaccine Market Report 2023 to 2027 - Featuring Walvax Biotechnology, Beijing Tiantan Biological Products, Sinovac Biotech and Shenzhen Kangtai Biological Products Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 31, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Other Health, Administration, Vaccination, Meningitis, Attenuated vaccine, Meningococcal disease, Rabies, MPSV4, Conjugate vaccine, Safety, Sinovac Biotech, PCV13, Expanded Program on Immunization, Infant, EPI, Sinopharm Group, Birth rate, Category, Parent, Pneumococcal polysaccharide vaccine, Forecasting, Policy, DTP, COVID-19, Category 2, R, Ageing, Pharmaceutical industry, Vaccine, Haemophilus, Immunization

As a result, China has drawn significant attention to the vaccine industry to play a representative role.

Key Points: 
  • As a result, China has drawn significant attention to the vaccine industry to play a representative role.
  • In addition, it is a closed market with a solid local vaccine industry, access to which is challenging for Western players.
  • Meningococcal Meningitis, Pneumococcal, and DTP Vaccine market are expected to control a significant portion of China's vaccine market.
  • The major players covered in the report are Sinopharm Group, Hualan Biological Engineering Inc, Chongqing Zhifei Biological Products Co Ltd, Walvax Biotechnology Co Ltd, Beijing Tiantan Biological Products Corp Ltd, Sinovac Biotech, and Shenzhen Kangtai Biological Products Co Ltd.

Philips Releases Professional Monitor that Highlights Impressive Color Features

Retrieved on: 
Tuesday, January 31, 2023
EPI, OLED, Life, Hobby, Amazon, Marketing, High-dynamic-range television, KVM, Television

MILPITAS, Calif., Jan. 31, 2023 /PRNewswire-PRWeb/ -- EPI, the leading display specialist and brand license partner for Philips monitors introduces the Philips 27E1N8900. Designed for professionals working from home and looking for a monitor that offers impressive visual contrast, the Philips monitor provides a novel experience. The main feature of this monitor, OLED, is known for its stark contrast and state-of-the-art pixel responsiveness.

Key Points: 
  • MILPITAS, Calif., Jan. 31, 2023 /PRNewswire-PRWeb/ -- EPI, the leading display specialist and brand license partner for Philips monitors introduces the Philips 27E1N8900.
  • Designed for professionals working from home and looking for a monitor that offers impressive visual contrast, the Philips monitor provides a novel experience.
  • The main feature of this monitor, OLED, is known for its stark contrast and state-of-the-art pixel responsiveness.
  • For these professions, it is necessary to have realistic color on the screen and this monitor is designed to do just that.

First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis

Retrieved on: 
Thursday, February 2, 2023
Safety, EPI, Patient, CF, First wave, Steatorrhea, Quality of life, Cystic fibrosis, Exocrine pancreatic insufficiency, SPAN, Malabsorption, CFA, Clinical trial, First, CNA, BOCA, Pharmaceutical industry

Patient dosing is expected to commence by mid-February with topline results from the study to be available by mid-2023.

Key Points: 
  • Patient dosing is expected to commence by mid-February with topline results from the study to be available by mid-2023.
  • “We are very pleased that patient screening has begun so soon after initiating the Phase 2 clinical trial,” said James Sapirstein, President and CEO of First Wave BioPharma.
  • “This urgency speaks to the collective focus of First Wave’s clinical development team, the investigators and trial sites, and our CRO partner to conduct a successful Phase 2 clinical trial.
  • “Exocrine pancreatic insufficiency is a debilitating condition that is challenging to manage for individuals with cystic fibrosis with currently available porcine-derived therapies,” said Dr. Steven Boas, founder of the Cystic Fibrosis Institute and Cystic Fibrosis Center of Chicago.

First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis

Retrieved on: 
Tuesday, January 31, 2023
Food, PERT, Safety, EPI, Patient, First wave, Stomach, IND, Cystic fibrosis, Exocrine pancreatic insufficiency, SPAN, CFA, Capsule, Malabsorption, Clinical trial, FDA, Gastrointestinal tract, CNA, Investigational New Drug, BOCA, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Enzyme replacement therapy, Pharmaceutical industry

The Phase 2 multi-center study is designed to investigate the safety, tolerability and efficacy of an enteric microgranule delivery formulation for adrulipase in a titrated dose-escalation study involving an estimated twelve (12) patients.

Key Points: 
  • The Phase 2 multi-center study is designed to investigate the safety, tolerability and efficacy of an enteric microgranule delivery formulation for adrulipase in a titrated dose-escalation study involving an estimated twelve (12) patients.
  • First Wave BioPharma expects to initiate patient screening in early February 2023, with topline data anticipated by mid-2023.
  • “We are very pleased to announce the initiation of the Phase 2 clinical trial investigating our new formulation of adrulipase as a potential treatment for EPI associated with cystic fibrosis and chronic pancreatitis,” said James Sapirstein, President and CEO of First Wave BioPharma.
  • The Phase 2 SPAN trial is designed to investigate the safety, tolerability and efficacy of a new enteric microgranule formulation of adrulipase.

First Wave BioPharma Announces Expansion of Adrulipase Intellectual Property Portfolio

Retrieved on: 
Wednesday, January 25, 2023
Food, PERT, EPI, IND, First wave, Stomach, Steatorrhea, Cystic fibrosis, Exocrine pancreatic insufficiency, Intellectual property, Therapy, CP, Capsule, IP, Patient, Patent, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Investigational New Drug, BOCA, Research, Pharmaceutical industry

Provisional Patent application involving composition of matter improvements designed to enhance adrulipase’s delayed release profile.

Key Points: 
  • Provisional Patent application involving composition of matter improvements designed to enhance adrulipase’s delayed release profile.
  • This filing adds to the growing intellectual property (IP) portfolio governing adrulipase, which includes patent applications governing adrulipase formulation and methods of use and the utilization of enteric formulations in the delivery of adrulipase.
  • Upon IND clearance, First Wave expects to initiate a Phase 2 trial at the beginning of 2023.
  • “Enhancing the IP portfolio protecting adrulipase and the microgranule drug delivery formulation is an important value-building opportunity for First Wave as we prepare to soon initiate the Phase 2 clinical trial of adrulipase in exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis,” said James Sapirstein, President and CEO of First Wave BioPharma.

North America Silicon EPI Wafer Market Report 2023: Sector to Reach $1.17 Billion by 2028 with an 8.5% CAGR

Retrieved on: 
Thursday, January 19, 2023
EPI, COVID-19, LED, Epitaxy, Tablet, Silicon, MOS, Bipolar, Diffusion, Growth, Health, Center for Urban and Regional Analysis, Electronics, Computer, Gallium nitride, Shin-Etsu Chemical, MEMS, QST, Borosilicate glass

An epitaxial wafer, also known as an EPI wafer, is created by placing a layer of epitaxial silicon single crystal on a single crystal silicon wafer.

Key Points: 
  • An epitaxial wafer, also known as an EPI wafer, is created by placing a layer of epitaxial silicon single crystal on a single crystal silicon wafer.
  • This is likely to drive the North America silicon EPI wafer market at a notable CAGR during the forecast period.
  • The North America silicon EPI wafer market is segmented on the basis of wafer size, application, end user, type, and country.
  • Based on country, the North America silicon EPI wafer market is segmented into the US, Mexico, and Canada.